Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants

Schizophrenia Research

Volumn 98, Issue 1-3, 2008, Pages 47-54

  Ellingrod, Vicki L ^a,b   Miller, Del D ^c   Taylor, Stephan F ^b   Moline, Jessica ^a   Holman, Timothy ^c   Kerr, Jane ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antipsychotics; Folate; Metabolic syndrome; MTFHR; Pharmacogenomics; Schizophrenia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FOLIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EXPOSURE; ENZYME ACTIVITY; FEMALE; FOLATE METABOLISM; GENE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MTHFR GENE; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHARMACOGENETICS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 36849066949     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.09.030     Document Type: Article

References (54)

1. Ames B.N. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat. Res. 475 1-2 (2001) 7-20
2. Applebaum J., Shimon H., Sela B.A., Belmaker R.H., and Levine J. Homocysteine levels in newly admitted schizophrenic patients. J. Psychiatr. Res. 38 4 (2004) 413-416
3. Brattstrom L., Wilcken D.E., Ohrvik J., and Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98 23 (1998) 2520-2526
4. Carlson C., Hornbuckle K., Delisle F., Kryzhanovskaya L., Breier A., and Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur. Neuropsychopharmacol 16 5 (2006) 366-375
5. Danesh J., and Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J. Cardiovasc. Risk 5 4 (1998) 229-232
6. Friso S., and Choi S.W. Gene-nutrient interactions in one-carbon metabolism. Curr. Drug Metab. 6 1 (2005) 37-46
7. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10 1 (1995) 111-113
8. Gaulin B.D., Markowitz J.S., Caley C.F., Nesbitt L.A., and Dufresne R.L. Clozapine-associated elevation in serum triglycerides. Am. J. Psychiatry 156 8 (1999) 1270-1272
9. Gianfrancesco F., White R., Wang R.H., and Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 23 4 (2003) 328-335
10. Gueant J.L., Gueant-Rodriguez R.M., Anello G., et al. Genetic determinants of folate and vitamin b12 metabolism: a common pathway in neural tube defect and down syndrome?. Clin. Chem. Lab. Med. 41 11 (2003) 1473-1477
11. Gueant-Rodriguez R.M., Juilliere Y., Candito M., et al. Association of Mtrra66g polymorphism (but not of Mthfr C677t and A1298c, Mtra2756g, Tcn C776g) with homocysteine and coronary artery disease in the French population. Thromb. Haemost. 94 3 (2005) 510-515
12. Guo J.J., Keck Jr. P.E., Corey-Lisle P.K., et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J. Clin. Psychiatry 67 7 (2006) 1055-1061
13. Henderson D.C., Cagliero E., Gray C., et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry 157 6 (2000) 975-981
14. Henderson D.C., Cagliero E., Copeland P.M., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch. Gen. Psychiatry 62 1 (2005) 19-28
15. Huang T.L., and Chen J.F. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr. Res. 80 1 (2005) 55-59
16. Kato M.M., Currier M.B., Gomez C.M., Hall L., and Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim. Care Companion J. Clin. Psychiat. 6 2 (2004) 74-77
17. Kempisty B., Mostowska A., Gorska I., et al. Association of 677c> T polymorphism of methylenetetrahydrofolate reductase (Mthfr) gene with bipolar disorder and schizophrenia. Neurosci. Lett. 400 3 (2006) 267
18. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., and Schouten E.G. Mthfr 677c-> T polymorphism and risk of coronary heart disease: a meta-analysis. Jama 288 16 (2002) 2023-2031
19. Lambert B.L., Chou C.H., Chang K.Y., Tafesse E., and Carson W. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol. Drug Saf. 14 6 (2005) 417-425
20. Lee T.H., Cleeman J.I., Grundy S.M., et al. Executive summary of the Third Report of the National Cholesterol Education Program (Ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Iii). Jama 285 19 (2001) 2486-2497
21. Lee Y.S., Han D.H., Jeon C.M., et al. Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. Neuroreport 17 7 (2006) 743-746
22. Levine J., Stahl Z., Sela B.A., Gavendo S., Ruderman V., and Belmaker R.H. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159 10 (2002) 1790-1792
23. Lewis S.J., Ebrahim S., and Davey Smith G. Meta-analysis of Mthfr 677c-> T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?. Bmj 331 7524 (2005) 1053
24. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
25. Maggi S., Noale M., Gallina P., et al. metabolic syndrome, diabetes, and cardiovascular disease in an elderly caucasian cohort: the Italian longitudinal study on aging. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 61 5 (2006) 505-510
26. Martin Y.N., Salavaggione O.E., Eckloff B.W., Wieben E.D., Schaid D.J., and Weinshilboum R.M. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics 16 4 (2006) 265-277
27. Matthews R.G. Methylenetetrahydrofolate reductase: a common human polymorphism and its biochemical implications. Chem. Rec. 2 1 (2002) 4-12
28. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (Catie) schizophrenia trial and comparison with national estimates from Nhanes Iii. Schizophr. Res. 80 1 (2005) 19-32
29. McEvoy J.P., Lieberman J.A., Stroup T.S., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 4 (2006) 600-610
30. Moat S.J., Lang D., McDowell I.F., et al. Folate, homocysteine, endothelial function and cardiovascular disease. J. Nutr. Biochem 15 2 (2004) 64-79
31. Muntjewerff J.W., and Blom H.J. Aberrant folate status in schizophrenic patients: what is the evidence?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 7 (2005) 1133
32. Muntjewerff J.W., Kahn R.S., Blom H.J., and den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol. Psychiatry 11 2 (2005) 143
33. Nasrallah H.A. Metabolic findings from the Catie trial and their relation to tolerability. CNS Spectr. 11 7 Suppl 7 (2006) 32-39
34. Ollendorf D.A., Joyce A.T., and Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. MedGenMed 6 1 (2004) 5
35. Onat A., Hergenc G., Uyarel H., Can G., and Ozhan H. Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadolu Kardiyol. Derg. 6 4 (2006) 314-321
36. Oommen A.M., Griffin J.B., Sarath G., and Zempleni J. Roles for nutrients in epigenetic events. J. Nutr. Biochem 16 2 (2005) 74-77
37. Osser D.N., Najarian D.M., and Dufresne R.L. Olanzapine increases weight and serum triglyceride levels. J. Clin. Psychiatry 60 11 (1999) 767-770
38. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447 7143 (2007) 425-432
39. Roffman, J.L., Weiss, A.P., Purcell, S., et al., in press. Contribution of methylenetetrahydrofolate reductase (Mthfr) polymorphisms to negative symptoms in schizophrenia. Biol. Psychiatry [Epub ahead of print].
40. Saari K.M., Lindeman S.M., Viilo K.M., et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. J. Clin. Psychiatry 66 5 (2005) 559-563
41. Sernyak M.J., Gulanski B., and Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J. Clin. Psychiatry 66 11 (2005) 1463-1467
42. Setola E., Monti L.D., Galluccio E., et al. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur. J. Endocrinol. 151 4 (2004) 483-489
43. Simpson G.M. Atypical antipsychotics and the burden of disease. Am. J. Manag. Care 11 (2005) S235-S241 (8 Suppl)
44. Spivak B., Lamschtein C., Talmon Y., et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin. Neuropharmacol. 22 2 (1999) 98-101
45. Stamler J.S., Osborne J.A., Jaraki O., et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest. 91 1 (1993) 308-318
46. Tawakol A., Omland T., Gerhard M., Wu J.T., and Creager M.A. Hyperhomocyst(E)Inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95 5 (1997) 1119-1121
47. Ueland P.M., Refsum H., Beresford S.A., and Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am. J. Clin. Nutr. 72 2 (2000) 324-332
48. van der Put N.M., Gabreels F., Stevens E.M., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am. J. Hum. Genet. 62 5 (1998) 1044-1051
49. Volavka J., Czobor P., Sheitman B., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 159 2 (2002) 255-262
50. Wall R.T., Harlan J.M., Harker L.A., and Striker G.E. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb. Res. 18 1-2 (1980) 113-121
51. Wilson P.W., D'Agostino R.B., Parise H., Sullivan L., and Meigs J.B. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112 20 (2005) 3066-3072
52. Wilson P.W., Nam B.H., Pencina M., D'Agostino Sr. R.B., Benjamin E.J., and O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern. Med. 165 21 (2005) 2473-2478
53. Zintzaras E. C677t and A1298c methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatr. Genet. 16 3 (2006) 105-115
54. Zipursky R.B., Gu H., Green A.I., et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry 187 (2005) 537-543